(S1 (S (S (S (NP (NN Thrombospondin-2)) (VP (VBZ plays) (NP (DT a) (JJ protective) (NN role)) (PP (IN in) (NP (NN multistep) (NN carcinogenesis))))) (: :) (NP (DT a) (JJ novel) (NN host) (JJ anti-tumor) (NN defense) (NN mechanism))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ angiogenic) (NN switch)) (PP (IN during) (NP (NN tumorigenesis)))) (VP (VBZ is) (VP (VBN thought) (S (VP (TO to) (VP (VB be) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (NN change)) (PP (IN in) (NP (NP (DT the) (NN balance)) (PP (IN of) (NP (JJ pro-) (ADJP (ADJP (JJ angiogenic)) (CC and) (ADJP (JJ anti-angiogenic))) (NNS factors)))))))))))))) (. .)))
(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ biological) (NN role)) (PP (IN of) (NP (NP (DT the) (JJ endogenous) (NN angiogenesis) (NN inhibitor) (NN thrombospondin-2)) (PRN (-LRB- -LRB-) (NP (NN TSP-2)) (-RRB- -RRB-)))) (PP (IN during) (NP (NN multistep) (NN carcinogenesis))))))) (, ,) (NP (PRP we)) (VP (VBN subjected) (NP (ADJP (ADJP (JJ TSP-2-deficient)) (CC and) (ADJP (JJ wild-type))) (NNS mice)) (PP (TO to) (NP (DT a) (JJ chemical) (NN skin) (NN carcinogenesis) (NN regimen)))) (. .)))
(S1 (S (S (ADVP (RB Surprisingly)) (, ,) (NP (NN TSP-2) (NN expression)) (VP (VBD was) (ADVP (RB strongly)) (VP (VBN upregulated) (PP (IN in) (NP (NP (DT the) (JJ mesenchymal) (NN stroma)) (PP (IN of) (NP (JJ wild-type) (NNS mice))))) (PP (IN throughout) (NP (NP (DT the) (JJ consecutive) (NNS stages)) (PP (IN of) (NP (NN tumorigenesis))))) (SBAR (IN whereas) (S (NP (NP (DT the) (NN angiogenesis) (NN factor)) (, ,) (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (, ,)) (VP (VBD was) (VP (VBN induced) (ADVP (RB predominantly)) (PP (IN in) (NP (NN tumor) (NNS cells)))))))))) (. .)))
(S1 (S (S (NP (NN TSP-2) (NN deficiency)) (ADVP (RB dramatically)) (VP (VP (VBD enhanced) (NP (NP (NN susceptibility)) (PP (TO to) (NP (NN skin) (NN carcinogenesis))))) (CC and) (VP (VBD resulted) (PP (IN in) (NP (NP (VBN accelerated)) (CC and) (NP (VBN increased) (NN tumor) (NN formation))))))) (. .)))
(S1 (S (S (S (NP (DT The) (JJ angiogenic) (NN switch)) (VP (VBD occurred) (PP (IN in) (NP (NP (JJ early) (NNS stages)) (PP (IN of) (NP (JJ pre-malignant) (NN tumor) (NN formation))))))) (, ,) (CC and) (S (NP (NN tumor) (NN angiogenesis)) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN enhanced) (PP (IN in) (NP (JJ TSP-2-deficient) (NNS mice))))))) (. .)))
(S1 (S (S (SBAR (IN While) (S (NP (NN TSP-2) (NN deficiency)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (NN tumor) (NN differentiation)) (CC or) (NP (NN proliferation))))))) (, ,) (NP (NN tumor) (NN cell) (NN apoptosis)) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN reduced)))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VP (VBP reveal) (NP (NP (NN upregulation)) (PP (IN of) (NP (DT an) (JJ endogenous) (NN angiogenesis) (NN inhibitor)))) (PP (IN during) (NP (JJ multi) (NN step) (NN tumorigenesis)))) (CC and) (VP (VBP identify) (NP (VBN enhanced) (JJ stromal) (NN TSP-2) (NN expression)) (PP (IN as) (NP (DT a) (JJ novel) (NN host) (JJ anti-tumor) (NN defense) (NN mechanism)))))) (. .)))
